Status:
NOT_YET_RECRUITING
Role of BMP Pathway in MDS Progression
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Myelodysplastic Syndromes
Acute Myelogenous Leukemia
Eligibility:
All Genders
20+ years
Brief Summary
Myelodysplastic syndromes (MDS) are hematological cancers that can progress to acute myelogenous leukemia (AML). The involvement of the microenvironment in the maintenance, resistance and evolution of...
Eligibility Criteria
Inclusion
- Adult patients with myelodysplastic syndrome or suspected myelodysplastic syndrome according to the criteria defined by the World Health Organization Or
- Adult patient with suspicion of de novo acute myeloid leukemia at initial treatment
Exclusion
- Frontier MDS/myeloproliferative syndromes including chronic myelomonocytic leukemia
- MDS and AML having already benefited from cytotoxic treatment including hydroxycarbamide, azacytidine, intensive chemotherapy
- Patients objecting to their inclusion in the study
- Pregnant or breastfeeding women
- Patients under legal protection measure
Key Trial Info
Start Date :
January 27 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 27 2034
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06175923
Start Date
January 27 2024
End Date
January 27 2034
Last Update
January 23 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Lyon, France, 69229